CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conferenc

-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has received approval from the Australian Bellberry Human Research Ethics Committee (HREC) and clearance from the A

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro's website a

- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 -First participant dosing anticipated in first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced a submission to t

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company's first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder caused by single

Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases Total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, today announced a collaboration with Novo Nordisk, a global healthcare company, to advance the discovery and development

CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: 2024 Cantor Global Healthcare ConferenceTodd Chappell, Chief Operating Officer, will participate in a fireside chat on Tuesday, September 17, 2024, at 10:55 a.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference. Chardan's 8th Annual Genetic Medicines ConferenceRam Aiyar, Ph.D., Chief Executive

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor and scientific conferences: 2024 Wells Fargo Healthcare Conference Chief Executive Officer and President, Ram Aiyar, Ph.D., and Chief Financial Officer, Vineet Agarwal, will participate in 1x1 investor meetings on Wednesday, September 4, 2024. RNA Leaders USA CongressChief Operating Officer, Todd Chappell, will discuss the benefits of Korro's OPERA™ platform in a prese

Raymond James initiated coverage of Korro Bio with a rating of Strong Buy and set a new price target of $153.00

William Blair initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $180.00

H.C. Wainwright reiterated coverage of Korro Bio with a rating of Buy and set a new price target of $115.00 from $100.00 previously

BMO Capital Markets initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $120.00

H.C. Wainwright initiated coverage of Korro Bio with a rating of Buy and set a new price target of $100.00

RBC Capital Mkts initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $70.00

Piper Sandler initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $180.00

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $100 price target.

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model KRRO-110 showed 35µM of M-AAT one week post the first dose, with 0µM of M-AAT at baseline, increasing to 45µM of M-AAT at week 13

HC Wainwright & Co. analyst Mitchell Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and lowers the price target from $115 to $100.

BMO Capital analyst Kostas Biliouris maintains Korro Bio (NASDAQ:KRRO) with a Outperform and maintains $120 price target.

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.51) by 2.79 percent.

Financing led by Deep Track Capital with participation from other leading healthcare investorsPro-forma cash and cash equivalents of approximately $236 million before fees and expensesOn track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for KRRO-110

HC Wainwright & Co. analyst Mitchell Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and raises the price target from $100 to $115.

Piper Sandler analyst Yasmeen Rahimi maintains Korro Bio (NASDAQ:KRRO) with a Overweight and maintains $180 price target.

424B3 - Korro Bio, Inc. (0001703647) (Filer)

424B3 - Korro Bio, Inc. (0001703647) (Filer)

8-K - Korro Bio, Inc. (0001703647) (Filer)

424B3 - Korro Bio, Inc. (0001703647) (Filer)

424B3 - Korro Bio, Inc. (0001703647) (Filer)

10-Q - Korro Bio, Inc. (0001703647) (Filer)

8-K - Korro Bio, Inc. (0001703647) (Filer)

424B3 - Korro Bio, Inc. (0001703647) (Filer)

424B3 - Korro Bio, Inc. (0001703647) (Filer)

8-K - Korro Bio, Inc. (0001703647) (Filer)